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Introduction
Type 2 diabetes has reached pandemic proportions
across the world and the problem continues to grow
(1,2). Type 2 diabetes is a progressive disease, char-
acterised by diminishing b-cell function in the con-
text of insulin resistance, driven by obesity (3–5).
Impaired glucose tolerance precedes type 2 diabetes
and, by the time of clinical diagnosis, patients have
lost about half of their b-cell insulin-producing
capacity (3,6).
Therapy for type 2 diabetes needs to be steadily
intensiﬁed in line with the disease progression. Once
insulin therapy has been initiated – following the
failure of lifestyle changes and oral therapy to keep
patients in glycaemic control – there is often a need
for intensiﬁcation from basal insulin or a once-daily
(OD) regimen of premix insulin (comprising both
basal and prandial insulin components), as these are
two commonly prescribed ﬁrst-line insulin therapies
(7).
Although basal insulin, in combination with oral
antidiabetics (OADs), is an effective ﬁrst insulin ther-
apy for patients with poorly controlled type 2 diabetes
(8), its efﬁcacy eventually reaches a limit in some
patients because, while fasting blood glucose may be
at target, postprandial hyperglycaemia may continue
to rise and contribute to overall glycaemic levels (9).
In the large, international, PRESENT observational
study, the average baseline HbA1c in patients receiving
basal insulin (analogue or human) was greater than
9.3% (10), possibly at least in part because of impair-
ment of the second phase insulin release resulting
from b-cell glucotoxicity as diabetes progresses (4).
Intensiﬁed insulin therapy, which includes a rapid-
acting prandial component, is therefore appropriate
for these patients. Similarly, patients who are failing to
maintain glycaemic control on OD analogue premix
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What’s known
Intensiﬁcation of failing insulin therapy can be
achieved with BIAsp 30, dosed up to three-times-
daily. At present, international recommendations for
insulin intensiﬁcation using premix analogues are
limited and speciﬁc guidance on dosing is not
available for many scenarios. In October 2008, an
international, independent, expert panel met to
review the current guidelines for insulin
intensiﬁcation therapy with BIAsp 30 with the aim
of developing international practical guidance for
general and specialist practitioners.
What’s new
Treatment algorithms are presented to help
physicians intensify insulin therapy in patients with
type 2 diabetes: from basal insulin OD or BID to
BIAsp 30 BID, and from BIAsp 30 OD and BID to
BIAsp 30 BID and TID, respectively. Randomised
controlled trials and observational studies available
on PubMed, involving insulin therapy being
intensiﬁed with BIAsp 30, were reviewed to help
provide guidance on injection frequency, dose
transfer and titration.
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doi: 10.1111/j.1742-1241.2009.02192.x 1571need intensiﬁcation to twice daily (BID) to address the
postprandial glucose (PPG) excursions after more than
one meal per day (11,12). In the 1-2-3 study by Garber
et al., 41% of patients with type 2 diabetes who were
prescribed the analogue premix, biphasic insulin aspart
30⁄70 (BIAsp 30, comprising 30% prandial insulin
aspart and 70% basal protaminated aspart), achieved
HbA1c < 7.0% on an OD regimen over 16 weeks.
However, when the BIAsp 30 regimen was intensiﬁed
to BID and three-times daily (TID) (as necessary), 70%
and 77% of patients, respectively, were able to reach
this glycaemic goal (12).
International data from routine clinical practice
show that glycaemic control in patients with type 2
diabetes is poor on average, even in patients using
insulin: almost 50% of patients in the IMPROVE
observational study had HbA1c ‡ 9.0% at the base-
line visit (13). Improving treatment and disease man-
agement in type 2 diabetes is therefore crucial if
long-term vascular complications are to be mini-
mised (14–16), and intensiﬁcation of failing insulin
therapy is a key step in this process.
At present, international recommendations for
intensiﬁcation of insulin therapy using premix ana-
logues are limited. The American Association of
Clinical Endocrinologists’ (AACE) guidelines (17)
cover the following:
• Transition from a long-acting insulin analogue to
a premixed insulin analogue BID.
• Transition from a OD premixed insulin analogue
to a BID premixed insulin analogue.
In both scenarios, the recommendations are as fol-
lows: (following 1 : 1 dose transfer from basal insu-
lin) divide the total daily dose into two equal doses;
give half before breakfast, the other half before din-
ner; titrate to goal based on self-monitored blood
glucose data and diet history; the largest meal will
require a larger proportion of insulin; reduce the
total dose by 20% if the patient experiences recurrent
hypoglycaemia.
The AACE guidelines (17) thus do not cover the
possible intensiﬁcation from BID premix analogue to
TID premix analogue. The International Diabetes
Federation (IDF) guidelines (18) mention premixes
as viable intensiﬁcation options but offer no speciﬁc
guidance.
The BIAsp 30
1 EU label has the indication for pro-
gressing from OD to BID and from BID to TID, but
again no speciﬁc dosing guidelines are given for
intensiﬁcation. A recent consensus statement from
the UK recommended premix analogues BID
(intensifying to TID as required) as a treatment
option for patients with type 2 diabetes switching
from basal insulin (19). The initial dose was recom-
mended to be 80% of the ﬁnal basal dose with titra-
tion to target over 14 days. However, these
guidelines fail to include guidance on how the dose
should be split and titrated (19). New international
guidelines that cover all appropriate scenarios for
insulin intensiﬁcation with premixed analogues are
therefore needed.
As the diabetes pandemic grows, primary care
physicians will need to treat an increasing number of
patients with type 2 diabetes because there will be
too many cases for specialists to deal with (20).
Guidelines for insulin intensiﬁcation therefore need
to be straightforward, comprehensive and easily
implemented.
BIAsp 30 is the most prescribed analogue premix
and consequently has the largest evidence base in
terms of randomised controlled trials (RCTs) and
observational data. It follows that BIAsp 30 is there-
fore the analogue premix most likely to be used for
insulin intensiﬁcation, both from basal insulin and
from BIAsp 30 regimens: OD to BID and from BID
to TID. In October 2008, an independent interna-
tional expert panel – comprising the authors o7f this
report – met to review the current guidelines for
insulin intensiﬁcation therapy using BIAsp 30 in
patients with type 2 diabetes, with the aim of devel-
oping international practical guidance for general
and specialist practitioners.
Which patients need intensiﬁed
therapy? Clinical evidence for
intensiﬁcation with BIAsp 30
Patients who need intensiﬁed insulin therapy can
essentially be grouped into two categories: those who
started insulin with basal therapy and can no longer
maintain glycaemic control, and those using BIAsp
30 OD or BID and failing to maintain adequate gly-
caemic control.
Patients failing on basal insulin
Initiating insulin therapy with a basal insulin ana-
logue in patients failing on OAD therapy can be
effective (21,22), but intensiﬁcation may be needed
long-term. Few studies have addressed the question
of what happens to glycaemic control in patients
with type 2 diabetes failing to maintain glycaemic
goals on basal insulin, after a switch to BIAsp 30.
One RCT, the PREFER study, randomised 719
patients previously treated with two OADs with, or
without, basal insulin to either BIAsp 30 BID or
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aspart) (23). After 26 weeks of therapy, patients pre-
viously treated with basal insulin showed a reduction
in HbA1c of 0.75% (baseline level for the BIAsp 30
group was 8.40%). Although previous basal insulin
dose was not reported, the total daily BIAsp 30 dose
increased by 0.16 U⁄kg (from 0.47 to 0.63 U⁄kg)
from week 3 to week 26, with a 50⁄50 breakfast⁄din-
ner dose split (23).
Other evidence comes from large observational
studies: PRESENT and IMPROVE. These interna-
tional, non-interventional studies have reported on
the effectiveness and safety proﬁle of BIAsp 30 in
routine care in patients from a variety of prestudy
therapies, including basal insulin. In the PRESENT
analysis, glycaemic control at baseline was poor in
this patient group, with HbA1c > 9.3% for those
previously treated with human or analogue basal
insulin (10). After 6 months of BIAsp 30 therapy,
HbA1c decreased by a mean of 1.42% and 1.60%,
respectively. In terms of dosing, prestudy basal
insulin doses were 0.46 for human and 0.34 U⁄kg
for analogue. When the switch to BIAsp 30 was
made, doses were transferred, on average, approxi-
mately 1 : 1 for those coming from human basal
(mean total baseline BIAsp 30 dose: 0.50 U⁄kg) and
1 : 1.3 for those coming from analogue basal (mean
total baseline BIAsp 30 dose: 0.45 U⁄kg). During
the 6-month observation period, doses underwent
very little titration: ﬁnal doses were 0.56 and
0.48 U⁄kg, respectively (10). The increase in dose
when patients transferred from analogue basal insu-
lin to BIAsp 30 did not, however, have corollaries
in terms of hypoglycaemia; the rates of major and
minor hypoglycaemia were reduced following BIAsp
30 therapy compared with rates on analogue basal
insulin (major: 1.1–0.03, p < 0.05; minor: 2.9–2.2
episodes⁄patient⁄year, not statistically signiﬁcant,
p > 0.05) (10).
In the largest observational study to date of BIAsp
30 in routine care, IMPROVE, patients who were
switched from basal insulin to BIAsp 30 were, again,
in poor glycaemic control. Mean HbA1c was over
9.0% and patients had been diagnosed with type 2
diabetes, on average, more than 11 years previously
(24). After 26 weeks of BIAsp 30 therapy, reductions
in HbA1c were )1.64% in patients previously on
human basal insulin, and )1.83% in those previously
on analogue basal insulin. When switching to
BIAsp 30, the transfer of dose was 1 : 1.2 on average
(0.33–0.40 U⁄kg), but patients previously on OD
basal insulin were started on a lower BIAsp 30
dose than those previously on BID basal insulin
(0.36 and 0.44 U⁄kg, respectively). The majority of
patients (82%) were transferred to a BID BIAsp 30
regimen, regardless of prior basal insulin injection
frequency. The dose increase over the observation
period was similar in both groups (0.14 vs.
0.13 U⁄kg) (24).
To summarise, when BIAsp 30 BID was started
following basal insulin therapy in routine care, the
dose was transferred either 1 : 1 (if human basal)
or 1 : 1.3 (if analogue basal), without any safety
concerns and resulted in improved glycaemic
control. When switching from OD basal insulin, the
starting BIAsp 30 dose was smaller than when
switching from BID basal insulin, giving an average
dose transfer of 1 : 1.2. In addition, data from
RCTs have shown that BID BIAsp 30 administra-
tion resulted in a 50 : 50 breakfast⁄dinner dose
distribution.
Patients failing on OD or BID BIAsp 30
Initiating insulin therapy with BIAsp 30 OD is also a
successful strategy for improving glycaemic control in
patients with type 2 diabetes failing on oral therapy
(11,25–27). However, as demonstrated in the 1-2-3
study (12), BIAsp 30 OD will generally only get a
minority of patients to the HbA1c target of < 7.0%,
but the proportion is increased when dosing is inten-
siﬁed to BID and, if necessary, TID. In this study,
100 patients with type 2 diabetes, previously treated
with OADs (with or without basal insulin), were ini-
tiated with, or switched basal insulin therapy to,
BIAsp 30 OD for 16 weeks. After this time, 21% of
patients reached the IDF (18) HbA1c target of
< 6.5% and left the study. The remaining patients
were intensiﬁed to BIAsp 30 BID and, after 16 weeks,
to TID if this target had not been reached. This
intensiﬁcation strategy enabled 41%, 70% and 77%
of patients on OD, BID and TID to reach HbA1c
< 7.0%, respectively (12). The daily insulin dose
for patients who achieved the target HbA1c of
£ 6.5% on BIAsp 30 OD was 0.60 U⁄kg. For patients
who ﬁnished the study on BIAsp 30 BID, the total
dose almost doubled (due to the extra injection
and the relatively aggressive titration algorithm
used in this study), with a mean dose split close
to 50⁄50 (0.51⁄0.64 U⁄kg breakfast⁄dinner). For
those who ﬁnished on BIAsp 30 TID, the dose split
was 38⁄16⁄46% breakfast⁄lunch⁄dinner (0.58⁄0.25⁄
0.70 U⁄kg respectively).
Even when the total daily dose with BIAsp 30 TID
was smaller (0.59 U⁄kg), as in the REFORM study
(27), the breakfast⁄lunch⁄dinner dose split was
virtually the same: 34⁄17⁄49% (0.20⁄0.10⁄0.29 U⁄kg,
respectively). In this study, 101 patients inadequately
controlled on OAD combination therapy were rando-
mised to repaglinide 6 mg⁄day or metformin 2 g⁄day
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were not met [fasting plasma glucose (FPG) 4.0–
6.0 mmol⁄l, HbA1c < 6.5%], patients were intensiﬁed
to BIAsp 30 BID and then TID at 3, 6 or 9 months.
After 12 months, 42% of patients were receiving BIAsp
30 TID. Their mean HbA1c was 7.0%, and 26% of
patients achieved HbA1c < 6.5% (27).
The observed doubling of the BIAsp 30 dose when
intensifying from OD to BID in the 1-2-3 study (12)
was also seen in the trial by Bebakar et al. (11). Here,
191 patients with type 2 diabetes, previously insulin-
naı ¨ve, were randomised 2 : 1 to BIAsp 30 OD or to an
optimised OAD regimen. After 13 weeks, HbA1c was
reduced by a signiﬁcantly greater amount with BIAsp
30 OD than with optimised OADs ()1.16% vs.
)0.58%, p < 0.001), but only 25% of patients on
BIAsp 30 OD reached HbA1c < 7.0%. Those patients
with HbA1c > 8.5% or FPG > 7 mmol⁄l at this point
were intensiﬁed to BIAsp 30 BID for a further
13 weeks. At the end of the study, HbA1c was reduced
by )1.34% in those on BIAsp 30 BID and by )1.24%
in those who had remained on BIAsp 30 OD. The
starting insulin doses for those who ﬁnished on BIAsp
30 OD or BID were very similar: 0.17 and 0.16 U⁄kg,
but patients who intensiﬁed to a BID regimen ﬁnished
the 26-week trial with a BIAsp 30 dose approximately
double that of those who remained on an OD regimen:
0.22 vs. 0.43 U⁄kg (11).
To summarise, in treat-to-target intensiﬁcation
studies, the total dose of BIAsp 30 increased consid-
erably following the consecutive intensiﬁcation from
OD to BID to TID. The dose distribution of BID
BIAsp 30 administration was close to 50 : 50, while
in studies where patients had intensiﬁed to a TID
regimen, the highest dose of BIAsp 30 was given at
dinner, followed by the doses at breakfast and lunch.
On the basis of an assessment of the published data,
combined with many years of clinical experience, the
international expert panel agreed on the following
guideline for the intensiﬁcation of insulin therapy
using BIAsp 30.
Practical guidelines for insulin
intensiﬁcation with BIAsp 30
Switching from basal insulin OD or BID to
BIAsp 30 BID
A simple algorithm for switching patients from OD
or BID basal insulin (analogue or human) to BIAsp
30 BID is shown in Figure 1. Regardless of basal reg-
imen, if a patient has HbA1c higher than 8.0%, they
should be transferred to BIAsp 30 BID. If HbA1c is
moderately elevated (between 7.0% and 8.0%) but
FPG is within the normal range (4–6 mmol⁄l), the
suboptimal overall glycaemia is probably caused by
elevated PPG, thus the patient should be transferred
to BIAsp 30 BID as it provides prandial coverage as
well. If, however, HbA1c is between 7.0% and 8.0%,
and FPG is higher than 6 mmol⁄l, the existing basal
insulin dose(s) can be titrated further until the
patient achieves FPG below 6 mmol⁄l. If recurrent
hypoglycaemia limits uptitration of the basal dose, or
the daily dose reaches 0.5 U⁄kg (insulin units per kg
body weight), switching to BIAsp 30 BID can be
considered.
When switching a patient from basal insulin OD
or BID to BIAsp 30 BID, the points in Box 1 provide
some practical guidance.
Intensiﬁcation with BIAsp 30: from OD to BID
and from BID to TID
An algorithm for intensifying therapy from BIAsp
30 OD or BID to BIAsp 30 BID or TID is shown in
Figure 2. If a patient receiving BIAsp 30 OD or BID
has FPG (with or without predinner blood glucose
measurement) within the normal range (4–6 mmol⁄l),
Basal insulin OD or BID
HbA1c7–8% HbA1c> 8.0%
FPG > 6 mmol/l
(FPG >110 mg/dl)
FPG: 4–6 mmol/l
(FPG: 73–110 mg/dl)
Titrate basal insulin to
achieve
FPG < 6 mmol/l
(FPG < 110 mg/dl)
Switch to BIAsp 30 BID
Figure 1 A simple algorithm for the intensiﬁcation of basal insulin therapy once daily (OD) or twice daily (BID)
(analogue or human) to biphasic insulin aspart 30⁄70 (BIAsp 30) BID. FPG, fasting plasma glucose
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overall glycaemia is probably caused by elevated PPG
after a meal not covered by BIAsp 30, thus they should
be transferred to BIAsp 30 BID or TID (i.e., the
addition of just one daily injection). If, however, FPG
(with or without predinner blood glucose measure-
ment) is higher than 6 mmol⁄l, the existing BIAsp 30
dose(s) (OD or BID) should be titrated until the
patient achieves FPG below 6 mmol⁄l. If while doing
so hypoglycaemia
2 occurs, the patient should be
intensiﬁed to BIAsp 30 BID or TID (i.e., the addition
of just one daily injection).
When intensifying a patient’s therapy from BIAsp
30 OD or BID to BIAsp 30 BID or TID, the points in
Boxes 2 and 3 provide some practical guidance.
Titration algorithm for implementing the
above guidelines
This algorithm is taken from the INITIATE study
(28) and the current NovoMix 30 EU label (available
online at: http://www.emea.europa.eu/humandocs/
PDFs/EPAR/Novomix/H-308-PI-en.pdf)
Preprandial blood glucose value Dose change
< 4.4 mmol⁄l < 80 mg⁄dl )2U
4.4–6.1 mmol⁄l 80–110 mg⁄dl 0
6.2–7.8 mmol⁄l 111–140 mg⁄dl +2 U
7.9–10.0 mmol⁄l 141–180 mg⁄dl +4 U
> 10.0 mmol⁄l > 180 mg⁄dl +6 U
BIAsp 30 OD (pre dinner) or BIAsp 30 BID
FPG and/or pre dinner BG > 6 mmol/l
(110mg/dl)
FPG and/or pre dinner BG: 4–6 mmol/l
(73–110 mg/dl)
Titrate BIAsp 30 OD or BID to achieve
FPG and/or pre dinner BG < 6 mmol/l
(110 mg/dl)
HbA1c > 7.0%
If hypoglycaemia
occurs
Switch to BIAsp 30 BID or TID
Figure 2 A simple algorithm for intensifying therapy from biphasic insulin aspart 30⁄70 (BIAsp 30) once (OD) or twice
daily (BID) to BIAsp 30 twice or three-times daily (TID). FPG, fasting plasma glucose; BG, blood glucose
Box 2 Practical guidance for switching from BIAsp 30
OD to BID
Split the OD dose into equal breakfast and dinner doses
(50 : 50)
Titrate the doses preferably once a week according to the
algorithm below
Discontinue SUs
Continue metformin
Consider discontinuing TZDs as per local guidelines and
practice
Administer BIAsp 30 just before meals
Box 3 Practical guidance for switching from BIAsp 30
BID to TID
Add 2–6 U or 10% of total daily BIAsp 30 dose before lunch
Down-titration of morning dose ()2 to 4 U) may be needed
after adding the lunch dose
Titrate the doses preferably once a week according to the
algorithm below
Continue metformin
Consider discontinuing TZDs as per local guidelines and
practice
Administer BIAsp 30 just before meals
Box 1 Practical guidance for switching from basal
insulin OD or BID to BIAsp 30 BID
1 : 1 Total dose transfer to BIAsp 30
Split the dose 50 : 50 prebreakfast and predinner
Titrate the dose preferably once a week
Discontinue sulfonylureas (SUs)
Continue metformin
Consider discontinuing thiazolidinediones (TZDs) as per local
guidelines and practice
Administer BIAsp 30 just before meals
2Hypoglycaemia is deﬁned by the United Kingdom Pro-
spective Diabetes Study as a minor event if the patient is able
to self-treat the symptoms, unaided, and a major event if
third-party help is required or it necessitates medical inter-
vention (14).
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BIAsp 30 doses after intensifying basal insulin ther-
apy to BIAsp 30 BID, or intensifying BIAsp 30 OD
or BID to BIAsp 30 BID or TID, the following guid-
ance should be noted:
• The lowest of three previous days’ premeal levels
should be used.
• Always change the meal-time dose preceding the
measurement.
• The dose should not be increased if hypoglycaemia
occurs during these days.
• Dose adjustments can be made once a week until
target is reached.
• Only one dose at a time should be changed: the
evening dose should be titrated ﬁrst, followed by the
breakfast dose and ﬁnally the lunch dose as appro-
priate.
Considerations for dosing and
titration of BIAsp 30
When to down-titrate
Down-titrate the dose if major or recurrent minor
hypoglycaemia occurs (the United Kingdom Prospec-
tive Diabetes Study deﬁned minor hypoglycaemic
events as those for which the patient was able to
self-treat the symptoms, unaided, while major hypo-
glycaemic events were those that required third-party
help or necessitated medical intervention) (14).
Patient demographics
• Guidance is aimed at the typical patient with type
2 diabetes.
• These guidelines assume no metabolic decompen-
sation (diabetic ketoacidosis, extreme hyperglyca-
emia, ﬂuctuating glucose levels).
• These guidelines may not be applicable in special
situations like pregnancy, acute coronary events,
patients treated in intensive care units, sepsis and
any other critical illnesses.
Other clinical insights
• When transferring a patient from biphasic human
insulin to BIAsp 30, start with the same dose and
regimen. When dose titration and further intensiﬁca-
tion are needed, follow the algorithm given above. A
recent study shows that patients can safely and effec-
tively self-titrate BIAsp 30 using an algorithm (29).
• Patients with a high body mass index (BMI) are
likely to require higher doses of BIAsp 30 than those
with a lower BMI and⁄or the elderly, who may be
more insulin-sensitive.
• Multiple doses of insulin are easier to administer
using injection pen-type devices (30).
• When the daily insulin dose in a OD regimen
nears 40–50 U, intensifying the regimen to BID is a
safer way to proceed than simply increasing the dose
further, as the dose can be split into two equal doses,
which reduces the chance of hypoglycaemia. Each of
these doses can then be titrated.
• For patients receiving BIAsp 30 TID, data from
RCTs indicate that the dose distribution should
approximate the ratio 2:1:3 , breakfast:lunch:din-
ner (or 33⁄17⁄50%).
• BIAsp 30 TID may be a useful alternative to basal–
bolus therapy for some patients, as fewer daily injec-
tions are required and only one insulin and one
device need be used, eliminating the potential for
mixing up insulins and hence incorrect dosing.
• Weight gain is a potential barrier to insulin ther-
apy in patients with type 2 diabetes; patients need to
have realistic expectations and manage potential
weight gain with a regimen of healthy diet and exer-
cise. Continuing metformin therapy might help min-
imise unwanted weight gain (31).
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